Clinical Trials on Observation of Neuromuscular Block in Belgium

Total 47 results

Onze Lieve Vrouw Hospital

Completed

Sugammadex and Heart Failure

Postoperative Neuromuscular Block

Belgium
Universitair Ziekenhuis Brussel

Completed

European Neuromuscular Monitoring Survey

Health Care Utilization | Availability of the Different Types of Anesthesia Neuromuscular Monitoring Devices Throughout European Hospitals | Medical Device Availability | Medical Staff Availability

Belgium
CuraVac
University Hospital, Antwerp; Leiden University Medical Center; Aepodia

Completed

Safety, Tolerability and Immunogenic Response of CV-MG01 in Patients With Myasthenia Gravis

Myasthenia Gravis

Belgium
CuraVac
University Hospital, Antwerp; Aepodia

Withdrawn

A Study to Evaluate the Efficacy of CV-MG01 (Myasterix) in Myasthenia Gravis

Myasthenia Gravis, Generalized

Belgium
Universitaire Ziekenhuizen KU Leuven

Recruiting

Hilotherapy-study on Prevention of Oxaliplatin-induced Peripheral Neuropathy (HILO-OXALI)

Quality of Life | Chemotherapy-induced Peripheral Neuropathy

Belgium
Centre Hospitalier Régional de la Citadelle

Completed

Safety and Efficacy Study of Pyridostigmine on Patients With Spinal Muscular Atrophy Type 3 (EMOTAS)

Spinal Muscular Atrophy Type 3

Belgium
University of Liege

Completed

Multichannel tDCS to Reduce Hypertonia in Patients With Prolonged DOC

Disorder of Consciousness | Spasticity, Muscle | Minimally Conscious State | Vegetative State

Belgium
Centre Hospitalier Universitaire de Liege
Centre Hospitalier Régional de la Citadelle; SYSNAV

Recruiting

Exploratory Study on Predicting CIDP Patients' Decline During IV Immunoglobulin Treatment Adaptation Feasibility. (ActiCIDP)

Chronic Inflammatory Demyelinating Polyneuropathy

Belgium
argenx

Recruiting

Evaluating Long-term Safety of Efgartigimod Administered Intravenously and Efgartigimod PH20 Administered Subcutaneously in Children With Generalized Myasthenia Gravis (ADAPT Jr +)

Generalized Myasthenia Gravis

United States, Netherlands, Belgium, Poland, United Kingdom
University Hospital, Gasthuisberg
KU Leuven; Kom Op Tegen Kanker; Research Foundation Flanders

Recruiting

Assessing Timing of Enteral Feeding Support in Esophageal Cancer Patients on Muscle functTion and Survival (EFECTS)

Postoperative Complications | Muscle Weakness | Esophageal Cancer | Sarcopenia | Nutrition Aspect of Cancer | Jejunostomy; Complications

Belgium
Thomas More Kempen
Revalidatie & MS Centrum Overpelt

Unknown

Assessing Fatiguability of Tongue Muscles in MS

Multiple Sclerosis | Fatigue | Muscle Weakness | Deglutition Disorders | Exertion; Excess

Belgium
UCB Biopharma S.P.R.L.

Completed

Study to Test the Safety, Tolerability and Efficacy of UCB7665 in Subjects With Moderate to Severe Myasthenia Gravis

Myasthenia Gravis

United States, Belgium, Canada, Czechia, Denmark, Germany, Spain
argenx
Quintiles, Inc.

Completed

A Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness

Myasthenia Gravis

Italy, United States, Belgium, Canada, Netherlands, Poland, Spain, Sweden
argenx

Recruiting

Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis

Generalized Myasthenia Gravis

United Kingdom, Spain, United States, Austria, Germany, Belgium, Italy, Netherlands, France, Georgia, Poland, Canada
Grifols Therapeutics LLC

Completed

A Study to Assess the Efficacy and Safety of IGIV-C in Patients With Myasthenia Gravis Exacerbations

Myasthenia Gravis Exacerbations

Belgium, Poland, Canada, Argentina, Estonia, France, Hungary, Romania, Czechia, Latvia, Russian Federation, South Africa
CSL Behring

Completed

Study of Efficacy and Safety of Privigen in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy

Chronic Inflammatory Demyelinating Polyneuropathy

Poland, France, Germany, Belgium, Finland
argenx

Active, not recruiting

An Open-label Study to Investigate the Clinical Efficacy of Different Dosing Regimens of Efgartigimod IV in Patients With Generalized Myasthenia Gravis (ADAPT NXT)

Generalized Myasthenia Gravis

Georgia, United States, Austria, Belgium, Canada, France, Germany, Italy, Netherlands, Poland, Spain
Grifols Therapeutics LLC

Completed

Efficacy and Safety of IGIV-C in Corticosteroid Dependent Patients With Generalized Myasthenia Gravis

Myasthenia Gravis

United States, Belgium, Czechia, Estonia, Canada, France, Germany, Hungary, Poland, Lithuania
UCB Biopharma SRL

Completed

A Study to Assess Long-term Safety, Tolerability and Efficacy of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

United States, Belgium, Denmark, France, Germany, Netherlands, Spain, United Kingdom
argenx

Completed

Evaluating the Pharmacodynamic Noninferiority of Efgartigimod PH20 SC Administered Subcutaneously as Compared to Efgartigimod Administered Intravenously in Patients With Generalized Myasthenia Gravis (ADAPTsc)

Generalized Myasthenia Gravis

Spain, United States, Belgium, Georgia, Germany, Hungary, Italy, Japan, Netherlands, Poland, Russian Federation
argenx

Active, not recruiting

Evaluating the Long-Term Safety and Tolerability of Efgartigimod PH20 SC Administered Subcutaneously in Patients With Generalized Myasthenia Gravis (ADAPTSC+)

Generalized Myasthenia Gravis

United States, Belgium, Czechia, Georgia, Germany, Hungary, Italy, Japan, Netherlands, Poland, Russian Federation, Spain
argenx

Completed

A Safety and Tolerability Study of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness. (ADAPT+)

Generalized Myasthenia Gravis

United States, Belgium, Canada, Czechia, Denmark, France, Georgia, Germany, Hungary, Italy, Japan, Netherlands, Poland, Russian Federation, Serbia
Grifols Therapeutics LLC

Completed

A Study to Evaluate the Efficacy and Safety of IGIV-C in Symptomatic Subjects With Generalized Myasthenia Gravis

Myasthenia Gravis, Generalized

United States, Belgium, Czechia, Canada, Estonia, Lithuania, France, Germany, Hungary, Poland
Momenta Pharmaceuticals, Inc.

Terminated

An Extension Study of MOM-M281-004 to Evaluate the Safety, Tolerability, and Efficacy of M281 Administered to Patients With Generalized Myasthenia Gravis

Generalized Myasthenia Gravis

United States, Belgium, Canada, Germany, Italy, Poland, Spain, United Kingdom
Alexion Pharmaceuticals

Completed

Extension Study of ECU-MG-301 to Evaluate Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis

Refractory Generalized Myasthenia Gravis

Italy, United Kingdom, Spain, Belgium, Turkey, Japan, United States, Netherlands, Korea, Republic of, Argentina, Hungary, Sweden, Denmark, Brazil, Czechia, Finland, Canada
Momenta Pharmaceuticals, Inc.

Completed

A Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of M281 Administered to Adults With Generalized Myasthenia Gravis

Generalized Myasthenia Gravis

United States, Belgium, Canada, Germany, Italy, Poland, Spain, United Kingdom
Janssen Research & Development, LLC

Recruiting

A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis

Myasthenia Gravis

United States, Korea, Republic of, Japan, Taiwan, Denmark, Germany, Czechia, China, Spain, Belgium, Canada, Mexico, Poland, Italy, France, Australia, Sweden
argenx

Completed

An Efficacy and Safety Study of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness (ADAPT)

Generalized Myasthenia Gravis

United States, Belgium, Canada, Czechia, Denmark, France, Georgia, Germany, Hungary, Italy, Japan, Netherlands, Poland, Russian Federation, Serbia, United Kingdom
Hoffmann-La Roche
Association Française contre les Myopathies (AFM), Paris

Completed

Safety and Efficacy of Olesoxime (TRO19622) in 3-25 Years SMA Patients.

Spinal Muscular Atrophy Type II | Spinal Muscular Atrophy Type III Non Ambulant

Germany, Italy, France, Belgium, Poland, Netherlands, United Kingdom
UCB Biopharma SRL

Completed

A Study to Test Efficacy and Safety of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis

Generalized Myasthenia Gravis

United States, Belgium, Canada, Czechia, Denmark, France, Georgia, Germany, Hungary, Italy, Japan, Poland, Russian Federation, Serbia, Spain, Taiwan, United Kingdom
Alexion Pharmaceuticals

Completed

Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis (REGAIN Study)

Refractory Generalized Myasthenia Gravis

Korea, Republic of, United States, Spain, Canada, Netherlands, Belgium, Czechia, Denmark, Italy, Australia, Finland, Turkey, Germany, Greece, Brazil, Argentina, Japan, United Kingdom, Hungary, France, Sweden
Regeneron Pharmaceuticals

Recruiting

A Study to Examine the Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Adult Patients With Symptomatic Generalized Myasthenia Gravis (NIMBLE)

Generalized Myasthenia Gravis

Korea, Republic of, Japan, Spain, United States, Germany, Italy, Canada, Georgia, India, Belgium, Poland, Taiwan, Australia, Denmark, France, Turkey, Serbia, United Kingdom, Czechia
Pfizer

Terminated

A First in HumanTrial to Evaluate The Safety, Tolerability, And Pharmacokinetics Of PF-06755347

Healthy | Polyradiculoneuropathy, Chronic Inflammatory Demyelinating | Primary Immune Thrombocytopenia

Spain, United States, Belgium, United Kingdom, New Zealand
UCB Biopharma S.P.R.L.

Completed

A Study to Assess the Efficacy, Safety and Tolerability of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (MyCIDPchoice)

Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

United States, Belgium, Denmark, France, Germany, Netherlands, Spain, United Kingdom
Novartis Pharmaceuticals
Mitsubishi Tanabe Pharma Corporation

Completed

Evaluate Efficacy and Safety of Fingolimod 0.5 mg Orally Once Daily Versus Placebo in Chronic Inflammatory Demyelinating Polyradiculoneuropathy Patients.

Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Spain, United States, Belgium, Germany, Italy, Israel, Australia, France, United Kingdom, Netherlands, Czechia, Japan, Canada, Greece, Poland
CSL Behring
ICON Clinical Research

Completed

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20)

Polyradiculoneuropathy | Chronic Inflammatory Demyelinating Polyneuropathy

United States, Australia, Belgium, Canada, Czechia, Estonia, Finland, France, Germany, Israel, Italy, Japan, Netherlands, Poland, Spain, United Kingdom
Novartis Gene Therapies

Active, not recruiting

Long-term Follow-up Study of Patients Receiving Onasemnogene Abeparvovec-xioi

SMA | Spinal Muscular Atrophy Type II | Spinal Muscular Atrophy Type I | Spinal Muscular Atrophy Type III

United States, Belgium, France, Japan, United Kingdom, Italy, Taiwan, Australia, Canada
Scholar Rock, Inc.

Active, not recruiting

Long-Term Safety & Efficacy of Apitegromab in Patients With SMA Who Completed Previous Trials of Apitegromab-ONYX (ONYX)

Neuromuscular Diseases | Neuromuscular Manifestations | Atrophy | Muscular Atrophy | Spinal Muscular Atrophy | Muscular Atrophy, Spinal | Spinal Muscular Atrophy Type 3 | SMA | Anti-myostatin | Spinal Muscular Atrophy Type II

United States, Spain, Belgium, Germany, Netherlands, Poland, Italy, France, United Kingdom
Centre Hospitalier Universitaire de Liege
Sanofi; Takeda; University of Liege; Orchard Therapeutics; Centre Hospitalier Régional... and other collaborators

Recruiting

Baby Detect : Genomic Newborn Screening

Congenital Adrenal Hyperplasia | Hemophilia A | Hemophilia B | Mucopolysaccharidosis I | Mucopolysaccharidosis II | Cystic Fibrosis | Alpha 1-Antitrypsin Deficiency | Sickle Cell Disease | Fanconi Anemia | Chronic Granulomatous Disease | Wilson Disease | Severe Congenital Neutropenia | Ornithine Transcarbamylase... and other conditions

Belgium
Scholar Rock, Inc.

Active, not recruiting

Efficacy and Safety of Apitegromab in Patients With Later-Onset Spinal Muscular Atrophy Treated With Nusinersen or Risdiplam (SAPPHIRE)

Neuromuscular Diseases | Neuromuscular Manifestations | Atrophy | Muscular Atrophy | Spinal Muscular Atrophy | Muscular Atrophy, Spinal | Spinal Muscular Atrophy Type 3 | SMA | Spinal Muscular Atrophy Type 2 | Anti-myostatin

United States, Germany, Belgium, Spain, United Kingdom, Netherlands, France, Italy, Poland
Wave Life Sciences Ltd.

Terminated

Study of WVE-004 in Patients With C9orf72-associated Amyotrophic Lateral Sclerosis (ALS) or Frontotemporal Dementia (FTD) (FOCUS-C9)

ALS | FTD

Canada, Belgium, New Zealand, Netherlands, Australia, Sweden, United Kingdom, Ireland
Immunovant Sciences GmbH

Recruiting

To Assess Efficacy and Safety of Batoclimab in Adult Participants With Active CIDP

Chronic Inflammatory Demyelinating Polyneuropathy

United States, Italy, Norway, Greece, Poland, Sweden, Argentina, Belgium, Denmark, Finland, Germany, Portugal, Romania, Slovakia, Spain, Bulgaria, Korea, Republic of, United Kingdom
Transposon Therapeutics, Inc.

Active, not recruiting

A Phase 2a Study of TPN-101 in Patients With C9ORF72 ALS/FTD

Amyotrophic Lateral Sclerosis | Frontotemporal Dementia

Spain, United States, Belgium, France, Germany
argenx

Active, not recruiting

A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves) (ADHERE+)

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

United States, Austria, Belgium, Bulgaria, China, Czechia, Denmark, France, Georgia, Germany, Israel, Italy, Japan, Netherlands, Poland, Russian Federation, Serbia, Spain, Ukraine, United Kingdom, Latvia, Romania, Taiwan, Turkey
argenx

Completed

A Study to Assess the Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves) (ADHERE)

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

United States, Austria, Belgium, Bulgaria, China, Czechia, Denmark, France, Georgia, Germany, Hungary, Israel, Italy, Japan, Latvia, Netherlands, Poland, Romania, Russian Federation, Serbia, Spain, Taiwan, Turkey, Ukraine, United Kingdom
Erasmus Medical Center

Active, not recruiting

International Guillain-Barré Syndrome Outcome Study (IGOS)

Guillain-Barré Syndrome | Miller Fisher Syndrome

United States, Netherlands, United Kingdom, Bangladesh, Australia, Denmark, China, France, Germany, Spain, Argentina, Italy, Puerto Rico, South Africa, Belgium, Switzerland, Canada, Greece, Japan, Malaysia, Taiwan
Novartis Pharmaceuticals

Recruiting

Pediatric Long-Term Follow-up and Rollover Study

Glioblastoma | Astrocytoma | Anaplastic Astrocytoma | Neurofibromatosis Type 1 | Anaplastic Ganglioglioma | Anaplastic Pleomorphic Xanthoastrocytoma | Ganglioglioma | Pleomorphic Xanthoastrocytoma | Diffuse Astrocytoma | Anaplastic Oligodendroglioma | Pilocytic Astrocytoma | Gangliocytoma | Central Neurocytoma | Oligodendroglioma... and other conditions

United States, Belgium, Spain, Denmark, Germany, Czechia, Italy, Australia, Russian Federation, France, Brazil, Netherlands, Japan, Canada, Finland, Sweden, United Kingdom, Argentina, Israel

Clinical Trials on Observation of Neuromuscular Block in Belgium

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Cameroon

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations